Skip to content
Lower risk Drug recall · FDA · Published February 10, 2026

LEO Pharma Adbry Injection Recall: Wool Fiber Contamination Risk

LEO Pharma recalls Adbry (tralokinumab-ldrm) injections due to wool fiber contamination in one unit from a specific lot. This may cause infection if injected. Affected units have NDC codes 50222-350-91 or 50222-350-02.

🇺🇸 FDA recall #D-0339-2026DrugLEO Pharma ›
Take action

Contact the company

Recalling firmLEO PHARMA INC7 Giralda Farms · Madison, NJ 07940-1051
✎ GovInfoNow plain-language explainer

LEO Pharma is recalling Adbry injections that contain wool fiber, which could lead to infection if injected. This recall affects specific lots of the 300 mg/2mL injection product sold by prescription. Read more at govinfonow.com/recall/31485-leo-pharma-adbry-injection-recall-wool-fiber-contamination-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/31485-leo-pharma-adbry-injection-recall-wool-fiber-contamination-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0339-2026

Cite this page

“LEO Pharma Adbry Injection Recall: Wool Fiber Contamination Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31485-leo-pharma-adbry-injection-recall-wool-fiber-contamination-risk. Based on FDA recall #D-0339-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0339-2026%22&limit=1).

LEO Pharma Inc. recalled Adbry (tralokinumab-ldrm) injection nationwide due to a lack of sterility assurance caused by wool fiber particulate matter, the FDA announced on Feb. 10, 2026.

How to tell if you have it

  • Brand: LEO Pharma
  • Product: Adbry (tralokinumab-ldrm) injection, 300 mg/2mL
  • Packaging: Single dose Autoinjector
  • NDC: 50222-350-91 (1 unit), 50222-350-02 (2 units)
  • Lot codes: 003E24C, 003E24A
  • Expiration dates: 04/30/2027
  • Quantity: 11,407 units

The hazard

The recall addresses a lack of assurance of sterility because lab tests identified wool fiber particulate matter in one unit from the affected lots. The FDA stated this defect poses a risk to patients using the drug.

Context

GovInfoNow's records show LEO Pharma Inc. has two other recalls on file since Jan. 16, 2017, including labeling issues with Calcipotriene Cream and Taclonex Topical Suspension in January 2017. Other recent recalls of similar products include Lupin Liraglutide 18mg/3mL Injection (April 24, 2026), Baxter 0.9% Sodium Chloride Injection (Aug. 17, 2026), and B. Braun Medical Lactated Ringer's Injection (April 28, 2026).

How to tell if you have this one

Check the NDC code on the product label: 50222-350-91 for single-dose autoinjectors or 50222-350-02 for two-dose autoinjectors. The product is only available by prescription and is labeled as a sample not for sale.

  • Brand
    LEO Pharma
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Label

    Look for the NDC code 50222-350-91 or 50222-350-02 on the product label to identify affected units.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 22 days after the firm started it.

1. Firm started the recall: Feb 10, 202612. FDA classified it Class II: Feb 23, 202623. Published in FDA’s Enforcement Report: Mar 4, 202632026
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0339-2026 (February 10, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0339-2026 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA